Clovis Oncology Common Stock Net 2010-2022 | CLVSQ

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Clovis Oncology common stock net from 2010 to 2022. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Clovis Oncology common stock net from 2010 to 2022. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$245.4B
Amgen (AMGN)	$157.5B
Gilead Sciences (GILD)	$146.4B
Vertex Pharmaceuticals (VRTX)	$100B
Bristol Myers Squibb (BMY)	$98.1B
CSL (CSLLY)	$85.5B
GSK (GSK)	$79.6B
Regeneron Pharmaceuticals (REGN)	$60.8B
Alnylam Pharmaceuticals (ALNY)	$59.9B
Argenex SE (ARGX)	$40.5B
BioNTech SE (BNTX)	$27.1B
Insmed (INSM)	$26.9B
Royalty Pharma (RPRX)	$20.9B
Biogen (BIIB)	$19.9B
Incyte (INCY)	$16.6B
Illumina (ILMN)	$15.5B
Genmab (GNMSF)	$15.3B
Genmab (GMAB)	$15B
Ascendis Pharma (ASND)	$11.9B
BioMarin Pharmaceutical (BMRN)	$11B
Moderna (MRNA)	$10.9B
QIAGEN (QGEN)	$10.8B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Exelixis (EXEL)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.5B
Bio-Techne Corp (TECH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Halozyme Therapeutics (HALO)	$8.1B
Roivant Sciences (ROIV)	$8B